nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2B6—Raloxifene—osteoporosis	0.0782	0.107	CbGbCtD
Nevirapine—CYP2B6—Ethinyl Estradiol—osteoporosis	0.0755	0.104	CbGbCtD
Nevirapine—CYP1A2—Estropipate—osteoporosis	0.0687	0.0942	CbGbCtD
Nevirapine—CYP2C9—Estropipate—osteoporosis	0.0619	0.0849	CbGbCtD
Nevirapine—CYP2B6—Cholecalciferol—osteoporosis	0.0604	0.0828	CbGbCtD
Nevirapine—CYP3A5—Estradiol—osteoporosis	0.0383	0.0526	CbGbCtD
Nevirapine—CYP3A4—Estropipate—osteoporosis	0.036	0.0494	CbGbCtD
Nevirapine—CYP3A4—Calcitriol—osteoporosis	0.036	0.0494	CbGbCtD
Nevirapine—CYP1A2—Conjugated Estrogens—osteoporosis	0.0325	0.0446	CbGbCtD
Nevirapine—CYP2C9—Cholecalciferol—osteoporosis	0.0319	0.0437	CbGbCtD
Nevirapine—CYP2D6—Cholecalciferol—osteoporosis	0.0292	0.04	CbGbCtD
Nevirapine—CYP3A4—Ergocalciferol—osteoporosis	0.0288	0.0395	CbGbCtD
Nevirapine—CYP1A2—Estradiol—osteoporosis	0.0285	0.0391	CbGbCtD
Nevirapine—CYP2C9—Estradiol—osteoporosis	0.0257	0.0352	CbGbCtD
Nevirapine—CYP3A4—Raloxifene—osteoporosis	0.024	0.0329	CbGbCtD
Nevirapine—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0232	0.0318	CbGbCtD
Nevirapine—CYP3A4—Cholecalciferol—osteoporosis	0.0186	0.0254	CbGbCtD
Nevirapine—CYP3A4—Conjugated Estrogens—osteoporosis	0.017	0.0233	CbGbCtD
Nevirapine—CYP3A4—Estradiol—osteoporosis	0.015	0.0205	CbGbCtD
Nevirapine—Fatigue—Ibandronate—osteoporosis	0.000395	0.00146	CcSEcCtD
Nevirapine—Arthralgia—Risedronate—osteoporosis	0.000394	0.00146	CcSEcCtD
Nevirapine—Myalgia—Risedronate—osteoporosis	0.000394	0.00146	CcSEcCtD
Nevirapine—Pain—Ibandronate—osteoporosis	0.000392	0.00145	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000391	0.00145	CcSEcCtD
Nevirapine—Pruritus—Etidronic acid—osteoporosis	0.000391	0.00144	CcSEcCtD
Nevirapine—Gastrointestinal pain—Estropipate—osteoporosis	0.000391	0.00144	CcSEcCtD
Nevirapine—Decreased appetite—Calcitriol—osteoporosis	0.00039	0.00144	CcSEcCtD
Nevirapine—Neuropathy peripheral—Estradiol—osteoporosis	0.000388	0.00144	CcSEcCtD
Nevirapine—Feeling abnormal—Alendronate—osteoporosis	0.000388	0.00143	CcSEcCtD
Nevirapine—Oedema—Ethinyl Estradiol—osteoporosis	0.000387	0.00143	CcSEcCtD
Nevirapine—Erythema—Conjugated Estrogens—osteoporosis	0.000387	0.00143	CcSEcCtD
Nevirapine—Jaundice—Estradiol—osteoporosis	0.000386	0.00143	CcSEcCtD
Nevirapine—Conjunctivitis—Estradiol—osteoporosis	0.000385	0.00142	CcSEcCtD
Nevirapine—Gastrointestinal pain—Alendronate—osteoporosis	0.000385	0.00142	CcSEcCtD
Nevirapine—Pain—Calcitriol—osteoporosis	0.000383	0.00142	CcSEcCtD
Nevirapine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00038	0.0014	CcSEcCtD
Nevirapine—Urticaria—Estropipate—osteoporosis	0.000379	0.0014	CcSEcCtD
Nevirapine—Gastrointestinal pain—Raloxifene—osteoporosis	0.000378	0.0014	CcSEcCtD
Nevirapine—Diarrhoea—Etidronic acid—osteoporosis	0.000378	0.0014	CcSEcCtD
Nevirapine—Abdominal pain—Estropipate—osteoporosis	0.000378	0.0014	CcSEcCtD
Nevirapine—Body temperature increased—Estropipate—osteoporosis	0.000378	0.0014	CcSEcCtD
Nevirapine—Feeling abnormal—Ibandronate—osteoporosis	0.000377	0.0014	CcSEcCtD
Nevirapine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000376	0.00139	CcSEcCtD
Nevirapine—Hepatobiliary disease—Estradiol—osteoporosis	0.000375	0.00139	CcSEcCtD
Nevirapine—Gastrointestinal pain—Ibandronate—osteoporosis	0.000375	0.00138	CcSEcCtD
Nevirapine—Myalgia—Pamidronate—osteoporosis	0.000374	0.00138	CcSEcCtD
Nevirapine—Arthralgia—Pamidronate—osteoporosis	0.000374	0.00138	CcSEcCtD
Nevirapine—Urticaria—Alendronate—osteoporosis	0.000374	0.00138	CcSEcCtD
Nevirapine—Ill-defined disorder—Zoledronate—osteoporosis	0.000373	0.00138	CcSEcCtD
Nevirapine—Abdominal pain—Alendronate—osteoporosis	0.000372	0.00138	CcSEcCtD
Nevirapine—Body temperature increased—Alendronate—osteoporosis	0.000372	0.00138	CcSEcCtD
Nevirapine—Anaemia—Zoledronate—osteoporosis	0.000371	0.00137	CcSEcCtD
Nevirapine—Nervous system disorder—Risedronate—osteoporosis	0.00037	0.00137	CcSEcCtD
Nevirapine—Discomfort—Pamidronate—osteoporosis	0.00037	0.00137	CcSEcCtD
Nevirapine—Angioedema—Zoledronate—osteoporosis	0.000367	0.00136	CcSEcCtD
Nevirapine—Skin disorder—Risedronate—osteoporosis	0.000367	0.00136	CcSEcCtD
Nevirapine—Gastrointestinal pain—Calcitriol—osteoporosis	0.000367	0.00136	CcSEcCtD
Nevirapine—Abdominal pain—Raloxifene—osteoporosis	0.000366	0.00135	CcSEcCtD
Nevirapine—Body temperature increased—Raloxifene—osteoporosis	0.000366	0.00135	CcSEcCtD
Nevirapine—Urticaria—Ibandronate—osteoporosis	0.000364	0.00135	CcSEcCtD
Nevirapine—Malaise—Zoledronate—osteoporosis	0.000362	0.00134	CcSEcCtD
Nevirapine—Abdominal pain—Ibandronate—osteoporosis	0.000362	0.00134	CcSEcCtD
Nevirapine—Body temperature increased—Ibandronate—osteoporosis	0.000362	0.00134	CcSEcCtD
Nevirapine—Oedema—Pamidronate—osteoporosis	0.000359	0.00133	CcSEcCtD
Nevirapine—Anaphylactic shock—Pamidronate—osteoporosis	0.000359	0.00133	CcSEcCtD
Nevirapine—Urticaria—Calcitriol—osteoporosis	0.000356	0.00132	CcSEcCtD
Nevirapine—Hepatitis—Estradiol—osteoporosis	0.000356	0.00131	CcSEcCtD
Nevirapine—Abdominal pain—Calcitriol—osteoporosis	0.000354	0.00131	CcSEcCtD
Nevirapine—Body temperature increased—Calcitriol—osteoporosis	0.000354	0.00131	CcSEcCtD
Nevirapine—Angioedema—Conjugated Estrogens—osteoporosis	0.000353	0.00131	CcSEcCtD
Nevirapine—Hypersensitivity—Estropipate—osteoporosis	0.000352	0.0013	CcSEcCtD
Nevirapine—Nervous system disorder—Pamidronate—osteoporosis	0.000352	0.0013	CcSEcCtD
Nevirapine—Thrombocytopenia—Pamidronate—osteoporosis	0.000351	0.0013	CcSEcCtD
Nevirapine—Vomiting—Etidronic acid—osteoporosis	0.000351	0.0013	CcSEcCtD
Nevirapine—Connective tissue disorder—Estradiol—osteoporosis	0.000349	0.00129	CcSEcCtD
Nevirapine—Rash—Etidronic acid—osteoporosis	0.000348	0.00129	CcSEcCtD
Nevirapine—Dermatitis—Etidronic acid—osteoporosis	0.000348	0.00129	CcSEcCtD
Nevirapine—Hypersensitivity—Alendronate—osteoporosis	0.000347	0.00128	CcSEcCtD
Nevirapine—Headache—Etidronic acid—osteoporosis	0.000346	0.00128	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000344	0.00127	CcSEcCtD
Nevirapine—Asthenia—Estropipate—osteoporosis	0.000343	0.00127	CcSEcCtD
Nevirapine—Anorexia—Pamidronate—osteoporosis	0.000342	0.00126	CcSEcCtD
Nevirapine—Arthralgia—Zoledronate—osteoporosis	0.000342	0.00126	CcSEcCtD
Nevirapine—Myalgia—Zoledronate—osteoporosis	0.000342	0.00126	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00034	0.00126	CcSEcCtD
Nevirapine—Paraesthesia—Risedronate—osteoporosis	0.000339	0.00125	CcSEcCtD
Nevirapine—Pruritus—Estropipate—osteoporosis	0.000338	0.00125	CcSEcCtD
Nevirapine—Discomfort—Zoledronate—osteoporosis	0.000338	0.00125	CcSEcCtD
Nevirapine—Asthenia—Alendronate—osteoporosis	0.000338	0.00125	CcSEcCtD
Nevirapine—Hypersensitivity—Ibandronate—osteoporosis	0.000337	0.00125	CcSEcCtD
Nevirapine—Erythema multiforme—Estradiol—osteoporosis	0.000336	0.00124	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000334	0.00124	CcSEcCtD
Nevirapine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000334	0.00123	CcSEcCtD
Nevirapine—Pruritus—Alendronate—osteoporosis	0.000333	0.00123	CcSEcCtD
Nevirapine—Hypersensitivity—Calcitriol—osteoporosis	0.00033	0.00122	CcSEcCtD
Nevirapine—Myalgia—Conjugated Estrogens—osteoporosis	0.000329	0.00122	CcSEcCtD
Nevirapine—Arthralgia—Conjugated Estrogens—osteoporosis	0.000329	0.00122	CcSEcCtD
Nevirapine—Asthenia—Ibandronate—osteoporosis	0.000329	0.00122	CcSEcCtD
Nevirapine—Nausea—Etidronic acid—osteoporosis	0.000328	0.00121	CcSEcCtD
Nevirapine—Oedema—Zoledronate—osteoporosis	0.000328	0.00121	CcSEcCtD
Nevirapine—Anaphylactic shock—Zoledronate—osteoporosis	0.000328	0.00121	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000327	0.00121	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000327	0.00121	CcSEcCtD
Nevirapine—Diarrhoea—Estropipate—osteoporosis	0.000327	0.00121	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000326	0.00121	CcSEcCtD
Nevirapine—Fatigue—Risedronate—osteoporosis	0.000325	0.0012	CcSEcCtD
Nevirapine—Pruritus—Ibandronate—osteoporosis	0.000324	0.0012	CcSEcCtD
Nevirapine—Pain—Risedronate—osteoporosis	0.000323	0.00119	CcSEcCtD
Nevirapine—Paraesthesia—Pamidronate—osteoporosis	0.000322	0.00119	CcSEcCtD
Nevirapine—Diarrhoea—Alendronate—osteoporosis	0.000322	0.00119	CcSEcCtD
Nevirapine—Asthenia—Calcitriol—osteoporosis	0.000322	0.00119	CcSEcCtD
Nevirapine—Nervous system disorder—Zoledronate—osteoporosis	0.000321	0.00119	CcSEcCtD
Nevirapine—Immune system disorder—Estradiol—osteoporosis	0.000321	0.00119	CcSEcCtD
Nevirapine—Thrombocytopenia—Zoledronate—osteoporosis	0.000321	0.00119	CcSEcCtD
Nevirapine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000319	0.00118	CcSEcCtD
Nevirapine—Somnolence—Pamidronate—osteoporosis	0.000319	0.00118	CcSEcCtD
Nevirapine—Skin disorder—Zoledronate—osteoporosis	0.000318	0.00118	CcSEcCtD
Nevirapine—Pruritus—Calcitriol—osteoporosis	0.000317	0.00117	CcSEcCtD
Nevirapine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000317	0.00117	CcSEcCtD
Nevirapine—Diarrhoea—Raloxifene—osteoporosis	0.000317	0.00117	CcSEcCtD
Nevirapine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000316	0.00117	CcSEcCtD
Nevirapine—Oedema—Conjugated Estrogens—osteoporosis	0.000316	0.00117	CcSEcCtD
Nevirapine—Diarrhoea—Ibandronate—osteoporosis	0.000313	0.00116	CcSEcCtD
Nevirapine—Anorexia—Zoledronate—osteoporosis	0.000312	0.00116	CcSEcCtD
Nevirapine—Decreased appetite—Pamidronate—osteoporosis	0.000312	0.00115	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00031	0.00115	CcSEcCtD
Nevirapine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00031	0.00114	CcSEcCtD
Nevirapine—Erythema—Estradiol—osteoporosis	0.00031	0.00114	CcSEcCtD
Nevirapine—Fatigue—Pamidronate—osteoporosis	0.000309	0.00114	CcSEcCtD
Nevirapine—Gastrointestinal pain—Risedronate—osteoporosis	0.000309	0.00114	CcSEcCtD
Nevirapine—Urticaria—Ethinyl Estradiol—osteoporosis	0.000308	0.00114	CcSEcCtD
Nevirapine—Pain—Pamidronate—osteoporosis	0.000307	0.00113	CcSEcCtD
Nevirapine—Diarrhoea—Calcitriol—osteoporosis	0.000307	0.00113	CcSEcCtD
Nevirapine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000307	0.00113	CcSEcCtD
Nevirapine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000306	0.00113	CcSEcCtD
Nevirapine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000306	0.00113	CcSEcCtD
Nevirapine—Vomiting—Estropipate—osteoporosis	0.000304	0.00112	CcSEcCtD
Nevirapine—Rash—Estropipate—osteoporosis	0.000301	0.00111	CcSEcCtD
Nevirapine—Dermatitis—Estropipate—osteoporosis	0.000301	0.00111	CcSEcCtD
Nevirapine—Anorexia—Conjugated Estrogens—osteoporosis	0.000301	0.00111	CcSEcCtD
Nevirapine—Urticaria—Risedronate—osteoporosis	0.0003	0.00111	CcSEcCtD
Nevirapine—Headache—Estropipate—osteoporosis	0.000299	0.00111	CcSEcCtD
Nevirapine—Vomiting—Alendronate—osteoporosis	0.000299	0.00111	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000299	0.0011	CcSEcCtD
Nevirapine—Body temperature increased—Risedronate—osteoporosis	0.000298	0.0011	CcSEcCtD
Nevirapine—Abdominal pain—Risedronate—osteoporosis	0.000298	0.0011	CcSEcCtD
Nevirapine—Rash—Alendronate—osteoporosis	0.000297	0.0011	CcSEcCtD
Nevirapine—Dermatitis—Alendronate—osteoporosis	0.000296	0.0011	CcSEcCtD
Nevirapine—Feeling abnormal—Pamidronate—osteoporosis	0.000296	0.00109	CcSEcCtD
Nevirapine—Headache—Alendronate—osteoporosis	0.000295	0.00109	CcSEcCtD
Nevirapine—Paraesthesia—Zoledronate—osteoporosis	0.000294	0.00109	CcSEcCtD
Nevirapine—Vomiting—Raloxifene—osteoporosis	0.000294	0.00109	CcSEcCtD
Nevirapine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000293	0.00109	CcSEcCtD
Nevirapine—Rash—Raloxifene—osteoporosis	0.000292	0.00108	CcSEcCtD
Nevirapine—Dermatitis—Raloxifene—osteoporosis	0.000291	0.00108	CcSEcCtD
Nevirapine—Somnolence—Zoledronate—osteoporosis	0.000291	0.00108	CcSEcCtD
Nevirapine—Vomiting—Ibandronate—osteoporosis	0.000291	0.00108	CcSEcCtD
Nevirapine—Headache—Raloxifene—osteoporosis	0.00029	0.00107	CcSEcCtD
Nevirapine—Rash—Ibandronate—osteoporosis	0.000289	0.00107	CcSEcCtD
Nevirapine—Dermatitis—Ibandronate—osteoporosis	0.000289	0.00107	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000288	0.00106	CcSEcCtD
Nevirapine—Ill-defined disorder—Estradiol—osteoporosis	0.000287	0.00106	CcSEcCtD
Nevirapine—Headache—Ibandronate—osteoporosis	0.000287	0.00106	CcSEcCtD
Nevirapine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000285	0.00105	CcSEcCtD
Nevirapine—Vomiting—Calcitriol—osteoporosis	0.000285	0.00105	CcSEcCtD
Nevirapine—Decreased appetite—Zoledronate—osteoporosis	0.000285	0.00105	CcSEcCtD
Nevirapine—Nausea—Estropipate—osteoporosis	0.000284	0.00105	CcSEcCtD
Nevirapine—Body temperature increased—Pamidronate—osteoporosis	0.000284	0.00105	CcSEcCtD
Nevirapine—Abdominal pain—Pamidronate—osteoporosis	0.000284	0.00105	CcSEcCtD
Nevirapine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000283	0.00105	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000283	0.00105	CcSEcCtD
Nevirapine—Angioedema—Estradiol—osteoporosis	0.000283	0.00105	CcSEcCtD
Nevirapine—Rash—Calcitriol—osteoporosis	0.000283	0.00105	CcSEcCtD
Nevirapine—Fatigue—Zoledronate—osteoporosis	0.000283	0.00104	CcSEcCtD
Nevirapine—Dermatitis—Calcitriol—osteoporosis	0.000282	0.00104	CcSEcCtD
Nevirapine—Headache—Calcitriol—osteoporosis	0.000281	0.00104	CcSEcCtD
Nevirapine—Somnolence—Conjugated Estrogens—osteoporosis	0.000281	0.00104	CcSEcCtD
Nevirapine—Pain—Zoledronate—osteoporosis	0.00028	0.00104	CcSEcCtD
Nevirapine—Nausea—Alendronate—osteoporosis	0.000279	0.00103	CcSEcCtD
Nevirapine—Malaise—Estradiol—osteoporosis	0.000279	0.00103	CcSEcCtD
Nevirapine—Hypersensitivity—Risedronate—osteoporosis	0.000278	0.00103	CcSEcCtD
Nevirapine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000278	0.00103	CcSEcCtD
Nevirapine—Nausea—Raloxifene—osteoporosis	0.000275	0.00102	CcSEcCtD
Nevirapine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000274	0.00101	CcSEcCtD
Nevirapine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000274	0.00101	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000272	0.00101	CcSEcCtD
Nevirapine—Fatigue—Conjugated Estrogens—osteoporosis	0.000272	0.00101	CcSEcCtD
Nevirapine—Nausea—Ibandronate—osteoporosis	0.000272	0.00101	CcSEcCtD
Nevirapine—Asthenia—Risedronate—osteoporosis	0.000271	0.001	CcSEcCtD
Nevirapine—Feeling abnormal—Zoledronate—osteoporosis	0.00027	0.000999	CcSEcCtD
Nevirapine—Pain—Conjugated Estrogens—osteoporosis	0.00027	0.000998	CcSEcCtD
Nevirapine—Gastrointestinal pain—Zoledronate—osteoporosis	0.000268	0.000991	CcSEcCtD
Nevirapine—Pruritus—Risedronate—osteoporosis	0.000267	0.000988	CcSEcCtD
Nevirapine—Nausea—Calcitriol—osteoporosis	0.000266	0.000985	CcSEcCtD
Nevirapine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000265	0.00098	CcSEcCtD
Nevirapine—Hypersensitivity—Pamidronate—osteoporosis	0.000264	0.000978	CcSEcCtD
Nevirapine—Myalgia—Estradiol—osteoporosis	0.000264	0.000974	CcSEcCtD
Nevirapine—Arthralgia—Estradiol—osteoporosis	0.000264	0.000974	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000262	0.000968	CcSEcCtD
Nevirapine—Urticaria—Zoledronate—osteoporosis	0.00026	0.000963	CcSEcCtD
Nevirapine—Discomfort—Estradiol—osteoporosis	0.00026	0.000963	CcSEcCtD
Nevirapine—Body temperature increased—Zoledronate—osteoporosis	0.000259	0.000958	CcSEcCtD
Nevirapine—Abdominal pain—Zoledronate—osteoporosis	0.000259	0.000958	CcSEcCtD
Nevirapine—Diarrhoea—Risedronate—osteoporosis	0.000258	0.000955	CcSEcCtD
Nevirapine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000258	0.000954	CcSEcCtD
Nevirapine—Asthenia—Pamidronate—osteoporosis	0.000257	0.000952	CcSEcCtD
Nevirapine—Pruritus—Pamidronate—osteoporosis	0.000254	0.000939	CcSEcCtD
Nevirapine—Oedema—Estradiol—osteoporosis	0.000253	0.000934	CcSEcCtD
Nevirapine—Anaphylactic shock—Estradiol—osteoporosis	0.000253	0.000934	CcSEcCtD
Nevirapine—Urticaria—Conjugated Estrogens—osteoporosis	0.000251	0.000927	CcSEcCtD
Nevirapine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00025	0.000923	CcSEcCtD
Nevirapine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00025	0.000923	CcSEcCtD
Nevirapine—Nervous system disorder—Estradiol—osteoporosis	0.000248	0.000916	CcSEcCtD
Nevirapine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000246	0.00091	CcSEcCtD
Nevirapine—Diarrhoea—Pamidronate—osteoporosis	0.000246	0.000908	CcSEcCtD
Nevirapine—Skin disorder—Estradiol—osteoporosis	0.000245	0.000907	CcSEcCtD
Nevirapine—Rash—Ethinyl Estradiol—osteoporosis	0.000244	0.000903	CcSEcCtD
Nevirapine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000244	0.000902	CcSEcCtD
Nevirapine—Headache—Ethinyl Estradiol—osteoporosis	0.000243	0.000897	CcSEcCtD
Nevirapine—Hypersensitivity—Zoledronate—osteoporosis	0.000242	0.000893	CcSEcCtD
Nevirapine—Vomiting—Risedronate—osteoporosis	0.00024	0.000887	CcSEcCtD
Nevirapine—Rash—Risedronate—osteoporosis	0.000238	0.00088	CcSEcCtD
Nevirapine—Dermatitis—Risedronate—osteoporosis	0.000238	0.000879	CcSEcCtD
Nevirapine—Headache—Risedronate—osteoporosis	0.000236	0.000874	CcSEcCtD
Nevirapine—Asthenia—Zoledronate—osteoporosis	0.000235	0.00087	CcSEcCtD
Nevirapine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000233	0.00086	CcSEcCtD
Nevirapine—Pruritus—Zoledronate—osteoporosis	0.000232	0.000858	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.00023	0.000851	CcSEcCtD
Nevirapine—Nausea—Ethinyl Estradiol—osteoporosis	0.00023	0.00085	CcSEcCtD
Nevirapine—Vomiting—Pamidronate—osteoporosis	0.000228	0.000844	CcSEcCtD
Nevirapine—Paraesthesia—Estradiol—osteoporosis	0.000227	0.000839	CcSEcCtD
Nevirapine—Asthenia—Conjugated Estrogens—osteoporosis	0.000226	0.000837	CcSEcCtD
Nevirapine—Rash—Pamidronate—osteoporosis	0.000226	0.000837	CcSEcCtD
Nevirapine—Dermatitis—Pamidronate—osteoporosis	0.000226	0.000836	CcSEcCtD
Nevirapine—Headache—Pamidronate—osteoporosis	0.000225	0.000831	CcSEcCtD
Nevirapine—Somnolence—Estradiol—osteoporosis	0.000225	0.00083	CcSEcCtD
Nevirapine—Diarrhoea—Zoledronate—osteoporosis	0.000224	0.000829	CcSEcCtD
Nevirapine—Nausea—Risedronate—osteoporosis	0.000224	0.000829	CcSEcCtD
Nevirapine—Pruritus—Conjugated Estrogens—osteoporosis	0.000223	0.000826	CcSEcCtD
Nevirapine—Decreased appetite—Estradiol—osteoporosis	0.00022	0.000812	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000218	0.000806	CcSEcCtD
Nevirapine—Fatigue—Estradiol—osteoporosis	0.000218	0.000805	CcSEcCtD
Nevirapine—Pain—Estradiol—osteoporosis	0.000216	0.000799	CcSEcCtD
Nevirapine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000216	0.000799	CcSEcCtD
Nevirapine—Nausea—Pamidronate—osteoporosis	0.000213	0.000788	CcSEcCtD
Nevirapine—Vomiting—Zoledronate—osteoporosis	0.000208	0.000771	CcSEcCtD
Nevirapine—Feeling abnormal—Estradiol—osteoporosis	0.000208	0.00077	CcSEcCtD
Nevirapine—Rash—Zoledronate—osteoporosis	0.000207	0.000764	CcSEcCtD
Nevirapine—Gastrointestinal pain—Estradiol—osteoporosis	0.000207	0.000764	CcSEcCtD
Nevirapine—Dermatitis—Zoledronate—osteoporosis	0.000206	0.000763	CcSEcCtD
Nevirapine—Headache—Zoledronate—osteoporosis	0.000205	0.000759	CcSEcCtD
Nevirapine—Vomiting—Conjugated Estrogens—osteoporosis	0.000201	0.000742	CcSEcCtD
Nevirapine—Urticaria—Estradiol—osteoporosis	0.000201	0.000742	CcSEcCtD
Nevirapine—Abdominal pain—Estradiol—osteoporosis	0.0002	0.000738	CcSEcCtD
Nevirapine—Body temperature increased—Estradiol—osteoporosis	0.0002	0.000738	CcSEcCtD
Nevirapine—Rash—Conjugated Estrogens—osteoporosis	0.000199	0.000736	CcSEcCtD
Nevirapine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000199	0.000735	CcSEcCtD
Nevirapine—Headache—Conjugated Estrogens—osteoporosis	0.000198	0.000731	CcSEcCtD
Nevirapine—Nausea—Zoledronate—osteoporosis	0.000195	0.00072	CcSEcCtD
Nevirapine—Nausea—Conjugated Estrogens—osteoporosis	0.000187	0.000693	CcSEcCtD
Nevirapine—Hypersensitivity—Estradiol—osteoporosis	0.000186	0.000688	CcSEcCtD
Nevirapine—Asthenia—Estradiol—osteoporosis	0.000181	0.00067	CcSEcCtD
Nevirapine—Pruritus—Estradiol—osteoporosis	0.000179	0.000661	CcSEcCtD
Nevirapine—Diarrhoea—Estradiol—osteoporosis	0.000173	0.000639	CcSEcCtD
Nevirapine—Vomiting—Estradiol—osteoporosis	0.000161	0.000594	CcSEcCtD
Nevirapine—Rash—Estradiol—osteoporosis	0.000159	0.000589	CcSEcCtD
Nevirapine—Dermatitis—Estradiol—osteoporosis	0.000159	0.000588	CcSEcCtD
Nevirapine—Headache—Estradiol—osteoporosis	0.000158	0.000585	CcSEcCtD
Nevirapine—Nausea—Estradiol—osteoporosis	0.00015	0.000555	CcSEcCtD
